The potential of this approach to address some of the inherent and emerging limitations of the cGAS-STING axis in cancer immunotherapy is considered, where it becomes evident that low doses of the DNA-damaging agent will be required to avoid detrimental immunotoxicity, and will need to be supported with the use of targeted nanoparticle delivery systems. This evidence concerns the gene STING1 and cancer.